Insuman Comb 25 Solostar

Insulin Human, the active ingredient in Insuman Comb 25 Solostar, is an insulin presented as a 25 units/mL solution for subcutaneous use. It treats hyperglycemia in patients with diabetes mellitus type 1 and type 2.

GNH USA supplies Insuman Comb 25 Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Clients benefit from reliable logistics, temperature‑controlled shipping, and comprehensive documentation for import clearance.

Insuman Comb 25 is an insulin preparation that acts on glucose metabolism in diabetes.

Diabetes mellitus type 1: improves basal and prandial glucose control. Diabetes mellitus type 2: provides combined basal and mealtime insulin coverage. Hyperglycemia in insulin‑deficient states: reduces elevated blood glucose levels.

Insuman Comb 25 may be associated with a range of adverse reactions.

Common Side Effects: - Hypoglycemia: symptoms of low blood sugar such as shakiness, sweating, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight due to improved glucose utilization. - Lipodystrophy: localized fat accumulation or loss at injection sites. - Edema: mild peripheral swelling, especially in the lower extremities. - Headache: transient mild headache without other neurological signs.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low blood glucose requiring emergency assistance. - Anaphylactic reaction: acute allergic response with hives, airway swelling, or hypotension. - Allergic dermatitis: widespread skin rash or eczema. - Insulin antibodies: formation of antibodies that may alter insulin action. - Hypokalemia: low serum potassium levels, particularly with high insulin doses. - Acute pancreatitis: sudden onset abdominal pain with elevated pancreatic enzymes.

When using Insuman Comb 25, several safety considerations should be observed.

Dose titration: adjust the dose based on regular glucose monitoring and clinical response. Hypoglycemia risk: educate patients to recognize symptoms and treat promptly. Concomitant medications: evaluate for additive glucose‑lowering effects. Renal impairment: use with caution and monitor renal function periodically. Pregnancy and lactation: discuss potential benefits and risks with a healthcare professional. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 25 can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Sulfonylureas: increased risk of severe hypoglycemia. - Meglitinides: additive glucose‑lowering effect, heightening hypoglycemia risk. - Beta‑blockers: may mask hypoglycemia symptoms, complicating detection.

Moderate Interactions (Monitor Closely): - ACE inhibitors: potential alterations in potassium balance. - Thiazide diuretics: may affect glucose control. - Corticosteroids: can raise blood glucose, requiring dose adjustments. - Oral contraceptives: variable impact on insulin requirements.